BIIB
Biogen Inc
Biogen Inc historical holders
total: 13
Pzena Investment Management Biogen Inc transactions over time
- Total transactions:
- 21
- New positions:
- 5
- Sold out:
- 5
- Added:
- 7
- Reduced:
- 4
- Held since:
- 2023 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2023 Q3
Richard Pzena has been an institutional investor in Biogen Inc (BIIB) since 2016 Q3. According to 2026 Q2 report, Richard Pzena doesn't hold any shares. The fund/company first acquired BIIB in 2016 Q3, initially purchasing 642 shares. Richard Pzena later completely sold out the position and reinvested in BIIB again in 2023 Q2. Since the initial investment, Pzena Investment Management has made 20 more transactions in this position.
When did Richard Pzena exit their BIIB position?
Richard Pzena no longer holds Biogen Inc (BIIB). They sold off their entire position in 2023 Q3, closing out an investment that began in 2016 Q3.
When did Richard Pzena first invest in BIIB?
Richard Pzena first invested in Biogen Inc (BIIB) in 2016 Q3 at the reported quarter-end price of $313.08 per share, acquiring 642 shares in their initial purchase.
What is Richard Pzena's average cost basis for BIIB?
Based on historical transaction data, Richard Pzena's estimated cost basis for Biogen Inc (BIIB) is approximately $284.85 per share. This represents their average reported price* across all buy transactions.
Has Richard Pzena reinvested in BIIB after selling?
Yes, Richard Pzena has shown renewed interest in Biogen Inc (BIIB). After completely selling their position, they reinitiated an investment in 2023 Q2, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $284.85
- Weighted AVG sell price:
- $284.85
BIIB transactions history by Pzena Investment Management
21 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q3
|
0.00%
|
0
|
$284.85
|
|
-100% (-1,618)
|
-0%
|
|
2023 Q2
|
0.00%
|
1,618
|
$284.85
|
$460,887
|
new
|
+0%
|
|
2022 Q4
|
0.00%
|
0
|
$267.20
|
|
-100% (-2,384)
|
-0%
|
|
2022 Q1
|
0.00%
|
2,384
|
$210.57
|
$502,000
|
new
|
+0%
|
|
2020 Q4
|
0.00%
|
$283.51
|
-100% (-2,857)
|
|||
|
2020 Q3
|
0.01%
|
$283.51
|
-11.90% (-386)
|
|||
|
2020 Q2
|
0.01%
|
$267.65
|
-93.12% (-43,908)
|
|||
|
2020 Q1
|
0.11%
|
$316.39
|
-5.07% (-2,519)
|
|||
|
2019 Q4
|
0.07%
|
$296.74
|
+1,455.59% (+46,477)
|
|||
|
2019 Q3
|
0.00%
|
$232.70
|
+37.75% (+875)
|
|||
|
2019 Q2
|
0.00%
|
$233.82
|
-5.43% (-133)
|
|||
|
2019 Q1
|
0.00%
|
$236.23
|
+16.38% (+345)
|
|||
|
2018 Q4
|
0.00%
|
$301.04
|
+12.98% (+242)
|
|||
|
2018 Q3
|
0.00%
|
$353.54
|
+4.13% (+74)
|
|||
|
2018 Q2
|
0.00%
|
$290.50
|
+2.46% (+43)
|
|||
|
2018 Q1
|
0.00%
|
$273.61
|
+87.65% (+816)
|
|||
|
2017 Q4
|
0.00%
|
$319.01
|
new
|
|||
|
2017 Q2
|
0.00%
|
$274.04
|
-100% (-759)
|
|||
|
2017 Q1
|
0.00%
|
$274.04
|
new
|
|||
|
2016 Q4
|
0.00%
|
$313.08
|
-100% (-642)
|
|||
|
2016 Q3
|
0.00%
|
$313.08
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.